



Experts taking care.

Boulder (Colorado, USA) / Frankfurt (Germany)  
October 10, 2017

---

## CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder Colorado

**CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO), has entered into definite agreements to acquire the former Hospira Boulder (Colorado) high containment API site from Pfizer, Inc. The closing of the transaction is anticipated to occur in November 2017.**

Located in proximity to the existing CordenPharma Colorado facility, Hospira Boulder produces Active Pharmaceutical Ingredients (APIs) and intermediate products with specialized capabilities in small to medium scale highly potent and cytotoxic API manufacturing. Previously owned by Pfizer / Hospira, the 54,000 square foot facility with more than 100 employees has API production capabilities ranging from very small scale up to 3,000 liters.

Integrated into the CordenPharma network, the combination of CordenPharma Colorado and Hospira Boulder's pharmaceutical supply business represents a unique opportunity to further strengthen CordenPharma's leading position as a premier CDMO supplier of Highly Potent & Oncology APIs to the pharmaceutical industry. CordenPharma will also enter into a multi-year supply arrangement with Pfizer, with the expectation that the agreement will help defray costs associated with running the site for the next few years while it adds new client work into the facility.

CordenPharma represents the global pharmaceutical manufacturing & service platform of International Chemical Investors Group (ICIG). "The acquisition will augment CordenPharma's Highly Potent & Oncology platform and integrated supply service offering in association with its drug product manufacturing expertise in the area of solid dosage and sterile injectables in CordenPharma Plankstadt (DE) and CordenPharma Latina (IT) respectively", says **Dr. Achim Riemann**, *Managing Director of ICIG*.

"This acquisition represents a further key milestone in CordenPharma's targeted acquisition strategy implemented over the last several years", adds **Patrick Schnitzer**, *Managing Director of ICIG*. As part of this strategy, CordenPharma continuously acquired API and Drug Product manufacturing capabilities over the last decade, including peptide and small molecules API plants as well as highly potent Drug Product sites in Italy, Germany and Belgium.

In addition, CordenPharma Colorado completed the construction of a new API process bay in 2016, equipped to handle highly potent compounds up to OEB Level 4, to accommodate increasing customer demand in this segment. "With this new acquisition, CordenPharma is uniquely positioned to provide pharma customers with the most comprehensive Highly

Potent & Oncology service in the industry, spanning the entire API and Drug Product supply chain at any stage from development to commercialization.” says **Dr. Michael Quirnbach**, *Vice President, Global Marketing & Sales, CordenPharma International*.

Hospira Boulder, to be renamed “CordenPharma Boulder,” will be managed by Brian McCudden, the current CEO of CordenPharma Colorado who was responsible for Hospira Boulder during one of his previous assignments as an employee of Hospira.

### **About International Chemical Investors Group**

International Chemical Investors Group (ICIG) is a privately owned industrial group with sales in excess of €2 billion and more than 6,000 employees worldwide. ICIG is focused on three main platforms: Pharmaceuticals - under the CordenPharma brand, Fine Chemicals - under the WeylChem brand and Chlorovinyls - under the VYNOVA brand. Since inception in 2004, ICIG has acquired 24 independent chemical and pharmaceutical businesses in Europe and the United States, all of which have origins in major global chemical or pharmaceutical corporations. For more information about International Chemical Investors Group visit [www.ic-investors.com](http://www.ic-investors.com).

### **About CordenPharma**

CordenPharma is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under five Technology Platforms – Peptides, Oligonucleotides, Lipids & Carbohydrates; Injectables; Highly Potent & Oncology; Small Molecules; and Antibiotics – CordenPharma experts translate complex processes, ideas and projects at any stage of development into high-value products. For more information visit [www.cordenpharma.com](http://www.cordenpharma.com).

### **Contact:**

#### **International Chemical Investors Group**

Sibel Cumcu  
An der Hauptwache 5  
60313 Frankfurt am Main  
Germany  
Phone: +49 69 506 999 0  
Email: [info@ic-investors.com](mailto:info@ic-investors.com)

#### **CordenPharma**

Abby Thompson  
2075 55th Street  
Boulder, Colorado 80301  
USA  
Phone: +1 (617) 909-5312  
Email: [abby.thompson@cordenpharma.com](mailto:abby.thompson@cordenpharma.com)